Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis.

ABSTRACT:

Aim

To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis.

Methods

A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data.

Results

Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU).

Conclusion

PGx-guided antidepressant prescribing improves the treatment of depression. However, the significa

SUBMITTER: Tesfamicael KG 

PROVIDER: S-EPMC11289719 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature